Condition: Acute Lymphoid Leukemia · Acute Myeloid Leukemia in Children · Sponsor: University Hospital, Tours
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.
This description comes directly from the study's public registry record.
Olivier HERAULT, MD-PhD · +33(0)234378902 · olivier.herault@univ-tours.fr
Wiebe de JONG, MSc · +33(0)247474680 · w.dejong@chu-tours.fr
Always discuss trial participation with your own doctor first.
| Service d'hématologie biologique-CHRU TOURS | Tours, France | Not Yet Recruiting |
| Service d'onco-hématologie pédiatrique -CHRU Tours | Tours, France | Recruiting |
| Service de chirurgie orthopédique pédiatrique -CHRU TOURS | Tours, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05792007